Get News Story – Page 15 – Just another WordPress site

Autoimmune Uveitis Market Expected to rise, 2034 | Tarsier Pharma, Eli Lilly and Company, Oculis Pharma, Eyevensys, Priovant Therapeutics, Inc., expected to drive market

“Autoimmune Uveitis market”

The Autoimmune Uveitis market growth is driven by factors like increase in the prevalence of Autoimmune Uveitis, investments in research and development, entry of emerging therapies during the study period 2020-2034.

The Autoimmune Uveitis market report also offers comprehensive insights into the Autoimmune Uveitis market size, share, Autoimmune Uveitis epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Autoimmune Uveitis market size growth forward.

Some of the key highlights from the Autoimmune Uveitis Market Insights Report:

Several key pharmaceutical companies, including Tarsier Pharma, Eli Lilly and Company, Oculis Pharma, Eyevensys, Priovant Therapeutics, Inc., and others, are developing novel products to improve the Autoimmune Uveitis treatment outlook.
In 2022, the Autoimmune Uveitis market size across the seven major markets (7MM) was approximately USD 1,290 million and is projected to grow significantly by 2034 at a notable compound annual growth rate (CAGR).
The United States accounted for the largest share, with a market size of around USD 840 million in 2022, while Italy had the smallest share, at USD 39 million, both of which are expected to increase by 2034. The highest number of autoimmune uveitis patients was observed in the US, followed by the EU4 countries, the UK, and Japan.
The distribution of autoimmune uveitis subtypes—such as anterior noninfectious uveitis (aNIU), pan-uveitis, and posterior uveitis—plays a critical role in determining treatment strategies, prognosis, and healthcare resource allocation. Diagnosed cases of aNIU were the most prevalent throughout the study period in the 7MM.
HUMIRA remains the only FDA-approved biologic treatment for autoimmune uveitis. In 2022, biologics dominated the market, contributing approximately USD 960 million of the total market size. The autoimmune uveitis treatment market is expected to witness substantial growth in the coming years.
The autoimmune uveitis treatment market is expected to grow during the forecast period, driven by the introduction of emerging therapies such as TRS01, OCS-02, and EYS606.

Strategise your business goals by understanding market dynamics @ Autoimmune Uveitis Market Landscape

Autoimmune Uveitis Overview

Autoimmune uveitis is an inflammatory condition affecting the uveal components of the eye, caused by autoimmune reactions to self-antigens or external triggers. It may occur as an isolated condition or alongside systemic autoimmune or auto-inflammatory diseases. While primarily impacting the uvea, it can also affect other eye structures. Autoimmune uveitis is classified as infectious or noninfectious, with the latter often linked to systemic autoimmune conditions. Symptoms include blurred vision, eye pain, photophobia, redness, and floaters, though children can be asymptomatic. Managing noninfectious uveitis (NIU) requires early and accurate diagnosis for timely treatment.

Diagnosis starts with a review of symptoms and a detailed examination of both the anterior and posterior eye segments. A systemic workup includes lab tests, chest X-rays, and advanced diagnostic tools like optical coherence tomography (OCT) and fluorescein angiography. Tests such as slit lamp examination, funduscopic exam, visual acuity, and ocular pressure evaluation confirm the condition. In ambiguous cases, serologic testing for syphilis and chest radiography for sarcoidosis or tuberculosis are recommended.

The diagnostic journey typically begins when patients experience risk factors such as infections, genetic predispositions, or post-surgical complications. They are referred by general physicians to ophthalmologists, who conduct specific diagnostic tests. However, there is no standardized diagnostic approach for uveitis, emphasizing the need for individualized evaluation and care.

Do you know the treatment paradigms for different countries? Download our Autoimmune Uveitis Market Sample Report

Autoimmune Uveitis Epidemiology Insights

In 2022, there were approximately 0.9 million diagnosed prevalent cases of uveitis and 0.6 million cases specifically of autoimmune uveitis across the 7MM, with these numbers expected to rise by 2034 due to an aging population. Uveitis can be classified as either infectious or noninfectious. According to epidemiological data, 0.1 million cases were infectious, while 0.7 million were noninfectious in 2022.
Noninfectious uveitis (NIU) was further categorized by anatomical location: anterior noninfectious uveitis (aNIU), posterior uveitis, intermediate uveitis, and pan-uveitis. Among these, aNIU accounted for the highest number of cases, with 0.5 million in 2022. This prevalence may be attributed to variations in autoimmune mechanisms, environmental factors, and the comparatively straightforward diagnosis of aNIU.
The United States had the largest share of diagnosed prevalent cases of autoimmune uveitis in 2022, with 0.29 million cases, a figure expected to grow by 2034. In Europe (EU4 and the UK), there were 0.26 million diagnosed cases, with Germany contributing the most at 73,000 cases. Meanwhile, Japan accounted for 17% of the total diagnosed prevalent cases in the 7MM, amounting to 0.1 million cases in 2022.

Autoimmune Uveitis Epidemiology Segmentation

DelveInsight’s Autoimmune Uveitis market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Autoimmune Uveitis historical patient pools and forecasted Autoimmune Uveitis patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Autoimmune Uveitis Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:

Autoimmune Uveitis Prevalence
Age-Specific Autoimmune Uveitis Prevalence
Gender-Specific Autoimmune Uveitis Prevalence
Diagnosed and Treatable Cases of Autoimmune Uveitis

Visit for more @ Autoimmune Uveitis Epidemiological Insights

Autoimmune Uveitis Market Insights:

Several major companies, including Alexion Pharmaceuticals, Novartis, and Roche, are leading the Autoimmune Uveitis (aHUS) treatment landscape. The market details, broken down by country and therapy, are outlined below.
According to DelveInsight’s patient-based forecasting model, the total aHUS market size in the 7MM was approximately USD 1,300 million in 2023, and significant growth is anticipated during the forecast period due to the introduction of new therapies.
In 2023, the United States accounted for the largest share of the aHUS market in the 7MM, approximately 70%, followed by Germany and France.
Among emerging therapies for aHUS, Novartis’ iptacopan and Roche’s crovalimab are expected to play a pivotal role in transforming the market. By 2034, iptacopan is projected to generate the highest revenue among emerging treatments, with nearly USD 100 million expected in the EU4 and the UK.

Autoimmune Uveitis Market Outlook

Managing noninfectious uveitis (NIU) and other autoimmune conditions is rarely straightforward, as it typically involves more than targeting a single molecule or mechanism. However, the approval of biologic treatments, such as HUMIRA, has marked significant progress, including specific options for NIU.

Local therapies for NIU primarily rely on corticosteroids, although intraocular injections of agents like sirolimus and methotrexate have also been explored. Current approved treatments include topical steroids, shorter-acting intraocular and periocular steroids such as triamcinolone acetonide, and sustained-release intravitreal implants like OZURDEX and YUTIQ.

The anticipated introduction of new therapies for autoimmune uveitis, including TRS01 eye drops (for noninfectious anterior uveitis), OCS-02 (for acute anterior uveitis), and EYS606: a combination product (for chronic noninfectious uveitis), is expected to significantly enhance the treatment landscape and positively influence the market.

Autoimmune Uveitis Marketed Drugs

YUTIQ: Eyepoint Pharmaceuticals
HUMIRA (Adalimumab): AbbVie Inc.

Autoimmune Uveitis Emerging Drugs

TRS01: Tarsier Pharma
OCS-02: Oculis Pharma

Autoimmune Uveitis Key Companies

Tarsier Pharma, Eli Lilly and Company, Oculis Pharma, Eyevensys, Priovant Therapeutics, Inc., and others

For more information, visit Autoimmune Uveitis Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Autoimmune Uveitis Market Report:

11 Years Forecast
7MM Coverage
Descriptive overview of Autoimmune Uveitis, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Autoimmune Uveitis epidemiology in the 7MM
Autoimmune Uveitis marketed and emerging therapies
Autoimmune Uveitis companies
Autoimmune Uveitis market drivers and barriers

Table of Contents:

1 Autoimmune Uveitis Market Key Comprehensive Insights

2 Autoimmune Uveitis Market Report Introduction

3 Competitive Intelligence Analysis for Autoimmune Uveitis

4 Autoimmune Uveitis Market Analysis Overview at a Glance

5 Executive Summary of Autoimmune Uveitis

6 Autoimmune Uveitis Epidemiology and Market Methodology

7 Autoimmune Uveitis Epidemiology and Patient Population

8 Autoimmune Uveitis Patient Journey

9 Autoimmune Uveitis Treatment Algorithm, Autoimmune Uveitis Current Treatment, and Medical Practices

10 Key Endpoints in Autoimmune Uveitis Clinical Trials

11 Autoimmune Uveitis Marketed Therapies

12 Autoimmune Uveitis Emerging Therapies

13 Autoimmune Uveitis: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Autoimmune Uveitis

16 Autoimmune Uveitis Market Key Opinion Leaders Reviews

18 Autoimmune Uveitis Market Drivers

19 Autoimmune Uveitis Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Autoimmune Uveitis Epidemiology 2034

DelveInsight’s “Autoimmune Uveitis – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Autoimmune Uveitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Autoimmune Uveitis Pipeline 2024

“Autoimmune Uveitis Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Autoimmune Uveitis market. A detailed picture of the Autoimmune Uveitis pipeline landscape is provided, which includes the disease overview and Autoimmune Uveitis treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Autoimmune Uveitis Market Expected to rise, 2034 | Tarsier Pharma, Eli Lilly and Company, Oculis Pharma, Eyevensys, Priovant Therapeutics, Inc., expected to drive market

Lupus Nephritis Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Therapies and Companies by DelveInsight

“Lupus Nephritis Treatment Market”

Lupus Nephritis companies are Aurinia Pharmaceuticals, Roche, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Otsuka Pharmaceutical, MorphoSys, Vertice Pharma, Pharmaceutical Associates Inc., Sun Pharmaceutical, Abbott, Johnson & Johnson Private Limited, Bayer, Sanofi, Sumitomo Corporation, LEO Pharma A/S, Cipla, and Nimble Pharmaceuticals, and others.

(Albany, USA) DelveInsight’s “Lupus Nephritis Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of Lupus Nephritis, historical and forecasted epidemiology as well as the Lupus Nephritis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Lupus Nephritis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Lupus Nephritis market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Lupus Nephritis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Lupus Nephritis market.

Request for a Free Sample Report @ Lupus Nephritis Market Forecast

Some facts of the Lupus Nephritis Market Report are:

According to DelveInsight, Lupus Nephritis market size is expected to grow at a decent CAGR by 2034.
The total lupus nephritis market size in the 7MM is approximately USD 1,120 million in 2022 and is projected to increase during the forecast period (2023–2034).
Leading Lupus Nephritis companies working in the market are Aurinia Pharmaceuticals, Roche, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Otsuka Pharmaceutical, MorphoSys, Vertice Pharma, Pharmaceutical Associates Inc., Sun Pharmaceutical, Abbott, Johnson & Johnson Private Limited, Bayer, Sanofi, Sumitomo Corporation, LEO Pharma A/S, Cipla, and Nimble Pharmaceuticals, and others.
Key Lupus Nephritis Therapies expected to launch in the market are BENLYSTA (belimumab), LUPKYNIS (voclosporin), Ianalumab (VAY736), SAPHNELO (anifrolumab), GAZYVA/GAZYVARO (obinutuzumab), Anifrolumab and others.
In November 2024, Adicet Bio announced that the first LN patient had been dosed in the Phase I clinical trial evaluating ADI-001 in autoimmune diseases.
In November 2024, Kyverna Therapeutics announced that it would present updated clinical data from LN patients treated with KYV-101 in ongoing Kyverna-sponsored KYSA-1 and KYSA-3 Phase I/II studies and named patient treatments.
In October 2024, Kezar Life Sciences suspended subject enrolment and patient dosing in the Phase II PALIZADE trial of zetomipzomib for active lupus nephritis.
In June 2024, Nkarta announced the initiation of Ntrust-I, a multi-center clinical trial of NKX019 in lupus nephritis, with the first patient in screening. The company also announced the clearance by the U.S. Food and Drug Administration (FDA) of its second Investigational New Drug (IND) application for NKX019 in autoimmune disease.
In June 2024, Adicet Bio announced that the US Food and Drug Administration (FDA) had granted Fast Track Designation to ADI-001 for the potential treatment of relapsed/refractory class III or class IV lupus nephritis.
In April 2024, Caribou Biosciences announced that it had received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for CB-010, an allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (KO), for the treatment of lupus nephritis (LN) and extrarenal lupus (ERL). The Phase 1, multicenter, open label GALLOP clinical trial of CB-010 in patients with LN and ERL is expected to initiate by year-end 2024.
In March 2024, Artiva Therapeutics is looking to dose the first patient in a Phase I/II trial assessing its cell therapy AlloNK in lupus nephritis (LN).

Lupus Nephritis Overview

Lupus nephritis (LN) is a serious complication of systemic lupus erythematosus (SLE), an autoimmune disease that affects multiple organs, including the kidneys. Lupus nephritis occurs when the immune system mistakenly attacks the kidneys, leading to inflammation and damage. It can present with various symptoms, such as blood or protein in the urine, swelling in the legs or ankles, high blood pressure, and reduced kidney function. Lupus nephritis can progress to chronic kidney disease and end-stage renal failure if left untreated. Diagnosis involves urine and blood tests, imaging studies, and kidney biopsy to assess the severity and type of kidney involvement. Treatment aims to control inflammation, preserve kidney function, and manage symptoms. This may include medications such as corticosteroids, immunosuppressants, and biologic therapies, as well as lifestyle modifications and close monitoring by healthcare providers. Early detection and treatment are crucial in improving outcomes for individuals with Lupus nephritis.

Learn more about Lupus Nephritis treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/lupus-nephritis-market

Lupus Nephritis Market

The Lupus Nephritis market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Lupus Nephritis market trends by analyzing the impact of current Lupus Nephritis therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Lupus Nephritis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Lupus Nephritis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Lupus Nephritis market in 7MM is expected to witness a major change in the study period 2020-2034.

Lupus Nephritis Epidemiology

The Lupus Nephritis epidemiology section provides insights into the historical and current Lupus Nephritis patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Lupus Nephritis market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Lupus Nephritis Epidemiology @ Lupus Nephritis Market Dynamics

Lupus Nephritis Drugs Uptake

This section focuses on the uptake rate of the potential Lupus Nephritis drugs recently launched in the Lupus Nephritis market or expected to be launched in 2020-2034. The analysis covers the Lupus Nephritis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Lupus Nephritis Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Lupus Nephritis market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Lupus Nephritis Pipeline Development Activities

The Lupus Nephritis report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Lupus Nephritis key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Lupus Nephritis pipeline development activities @ Lupus Nephritis Drugs Market

Lupus Nephritis Therapeutics Assessment

Major key companies are working proactively in the Lupus Nephritis Therapeutics market to develop novel therapies which will drive the Lupus Nephritis treatment markets in the upcoming years are Aurinia Pharmaceuticals, Roche, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Otsuka Pharmaceutical, MorphoSys, Vertice Pharma, Pharmaceutical Associates Inc., Sun Pharmaceutical, Abbott, Johnson & Johnson Private Limited, Bayer, Sanofi, Sumitomo Corporation, LEO Pharma A/S, Cipla, and Nimble Pharmaceuticals, and others.

Learn more about the emerging Lupus Nephritis therapies & key companies @ Lupus Nephritis Treatment Market

Lupus Nephritis Report Key Insights

1. Lupus Nephritis Patient Population

2. Lupus Nephritis Market Size and Trends

3. Key Cross Competition in the Lupus Nephritis Market

4. Lupus Nephritis Market Dynamics (Key Drivers and Barriers)

5. Lupus Nephritis Market Opportunities

6. Lupus Nephritis Therapeutic Approaches

7. Lupus Nephritis Pipeline Analysis

8. Lupus Nephritis Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Lupus Nephritis Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Lupus Nephritis Competitive Intelligence Analysis

4. Lupus Nephritis Market Overview at a Glance

5. Lupus Nephritis Disease Background and Overview

6. Lupus Nephritis Patient Journey

7. Lupus Nephritis Epidemiology and Patient Population

8. Lupus Nephritis Treatment Algorithm, Current Treatment, and Medical Practices

9. Lupus Nephritis Unmet Needs

10. Key Endpoints of Lupus Nephritis Treatment

11. Lupus Nephritis Marketed Products

12. Lupus Nephritis Emerging Therapies

13. Lupus Nephritis Seven Major Market Analysis

14. Attribute Analysis

15. Lupus Nephritis Market Outlook (7 major markets)

16. Lupus Nephritis Access and Reimbursement Overview

17. KOL Views on the Lupus Nephritis Market

18. Lupus Nephritis Market Drivers

19. Lupus Nephritis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Lupus Nephritis Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Therapies and Companies by DelveInsight

Developmental and Epileptic Encephalopathies Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Therapies and Companies by DelveInsight

“Developmental and Epileptic Encephalopathies Treatment Market”

Developmental and Epileptic Encephalopathy companies Takeda, Eisai, SK Life Science, Stoke Therapeutics, Harmony Biosciences/Epygenix, Longboard Pharmaceuticals, Praxis Precision Medicines, Neurocrine Biosciences, Bright Minds Biosciences, Cerecin, Encoded Therapeutics, Bloom Science, Neuroene Therapeutics, Regel Therapeutics, Jazz Pharmaceuticals, Biocodex, Zogenix, Lundbeck, Marinus Pharmaceuticals, Novartis, Eisai Pharmaceuticals, GlaxoSmithKline, Roche, others.

(Albany, USA) DelveInsight’s Developmental and Epileptic Encephalopathy Market Insights report includes a comprehensive understanding of current treatment practices, developmental and epileptic encephalopathy emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the Developmental and Epileptic Encephalopathy Market Report

As per DelveInsight analysis, the developmental and epileptic encephalopathy market size in the 7MM was approximately USD 2100 million in 2023.
According to the assessment done by DelveInsight, the estimated total DEE diagnosed prevalent cases in the 7MM were approximately 235K in 2021.
Leading developmental and epileptic encephalopathy companies working in the treatment market are Takeda, Eisai, SK Life Science, Stoke Therapeutics, Harmony Biosciences/Epygenix, Longboard Pharmaceuticals, Praxis Precision Medicines, Neurocrine Biosciences, Bright Minds Biosciences, Cerecin, Encoded Therapeutics, Bloom Science, IAMA Therapeutics, Ultragenyx Pharmaceutical, Neuroene Therapeutics, Regel Therapeutics, Jazz Pharmaceuticals, Biocodex, Zogenix (Acquired by UCB), Lundbeck, Marinus Pharmaceuticals, Novartis, Aquestive Therapeutics, Supernus Pharmaceuticals, Eisai Pharmaceuticals, GlaxoSmithKline, Meda Pharmaceuticals, Roche, Mallinckrodt Pharmaceuticals, Xenon Pharmaceuticals, Ovid Therapeutics, BioPharm Solutions and others.
The promising developmental and epileptic encephalopathy therapies in the pipeline include EPX-100, EPX-200, EPX-300, XEN 496, LP 352, STK-001, JBPOS0101, Soticlestat (OV935/TAK-935), Carisbamate, NBI-921352, NBI-827104, PRAX-562, and others.
The current therapeutic landscape of DEE in the United States is driven by current treatment practices which includes anti-epileptic drugs (AEDs), Epidiolex/Epidyolex (cannabidiol), Fintepla (Fenfluramine), Afinitor/Votubia (Everolimus), and others.

Discover which therapies are expected to grab the major developmental and epileptic encephalopathy market share @ Developmental and Epileptic Encephalopathy Market Forecast

Developmental and Epileptic Encephalopathy Overview

Developmental and epileptic encephalopathy is a seizure disorder characterized by infantile spasms, a type of seizure. Spasms typically appear before the age of one. The prognosis for developmental and epileptic encephalopathy is bleak. This rare disease, typically described as progressive and incurable, is also associated with severe physical and cognitive disabilities and unexplained death.

The most common cause of epileptic encephalopathy in childhood is structural abnormalities, which can be congenital (such as cortical malformations) or acquired (such as hypoxic-ischemic after the EEG often evolves to atypical hypsarrhythmia, which is a transient or multifocal spike and sharp waves 3-4 months after the onset of the disease. The diagnosis of these epileptic encephalopathies begins with an EEG which should include both the sleep and wake states.

Developmental and Epileptic Encephalopathy Epidemiology Segmentation

DelveInsight estimates that there were approximately 235K diagnosed prevalent cases of DEE in the 7MM in 2021.

Among the EU-4 countries, the diagnosed prevalent population of DEE was maximum in Germany in 2021.

The developmental and epileptic encephalopathy market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Diagnosed Prevalent Population of developmental and epileptic encephalopathy
Treated pool of developmental and epileptic encephalopathy

Download the report to understand which factors are driving developmental and epileptic encephalopathy epidemiology trends @ https://www.delveinsight.com/report-store/developmental-and-epileptic-encephalopathies-dee-market

Developmental and Epileptic Encephalopathy Treatment Market

Some of the general principles and approach to pediatric epilepsy treatment can be found in the epileptic encephalopathy treatment. The best anti-epileptic treatment is chosen based on the type of epilepsy syndrome. Although anti-seizure medications are commonly used, some types of seizures are notoriously difficult to control. It is the primary method of controlling epileptic seizures and is almost always the first class of therapy medications.

Some of the FDA-approved drugs used for DEE treatment include Epidiolex (Jazz Pharmaceuticals), Diacomit (Biocodex), Fintepla (Zogenix), Sabril (Lundbeck), Ztalmy (Marinus Pharmaceuticals), Afinitor Disperz/Votubia (Novartis), Sympazan (Aquestive Therapeutics), Trokendi XR (Supernus Pharmaceuticals), Onfi (Lundbeck), Banzel (Eisai Pharmaceuticals), Lamictal (GlaxoSmithKline), and others.

In some children, steroid therapy with adrenocorticotropic hormone (ACTH) or prednisone has been beneficial. When medications do not work well, a vagus nerve stimulator or the ketogenic diet may be considered in patients. Moreover, in children with seizures that begin in one area or involve only one side of the brain, epilepsy surgery may be an option. In these cases, a focal resection (removal of a single area) or a hemispherectomy (removal of the majority of one side of the brain) may be considered.

To know more about developmental and epileptic encephalopathy treatment options, visit @ Developmental and Epileptic Encephalopathy Treatment Market

Developmental and Epileptic Encephalopathy Pipeline Therapies and Key Companies

XEN496: Xenon Pharmaceuticals
Soticlestat: Takeda/Ovid Therapeutics
Carisbamate: SK Life Science
EPX-100 (Clemizole HCl): Epygenix
NBI-921352: Neurocrine Biosciences
STK-001: Stoke Therapeutics
NBI-827104: Neurocrine Biosciences
JBPOS0101: BioPharm Solutions
PRAX-562: Praxis Precision Medicines
EPX-200 (Lorcaserin): Epygenix
EPX-300: Epygenix
LP352: Longboard Pharmaceuticals

Learn more about the DEE FDA-approved drugs @ Developmental and Epileptic Encephalopathy Drugs Market

Developmental and Epileptic Encephalopathy Market Dynamics

The dynamics of developmental and epileptic encephalopathy market is anticipated to change in the coming years. Ztalmy, the first licensed therapy for CDKL5 deficiency disorder, was recently approved in the United States, boosting the developmental and epileptic encephalopathy market growth. Moreover, the void left by a lack of licensed medications will be filled by further R&D advancement. In addition, Epidiolex and Fintepla continue to add new prescribers and expand their existing prescriber base due to their strong uptake.

Furthermore, the current competitive scenario for DEE is limited to a few therapies. Currently, the DEE market appears to be an unexplored area by pharmaceutical companies, and thus the companies have a significant opportunity to capture the potential developmental and epileptic encephalopathy market space. Emerging drugs with improved seizure control may positively impact the developmental and epileptic encephalopathy market landscape and patients’ quality of life.

However, several factors are impeding the growth of the DEE market. Rare epileptic syndromes, such as LGS, Dravet Syndrome, and CDKL5 deficiency disorder, are extremely complex and heterogeneous diseases with multiple etiologies, posing several diagnostic challenges as the disease progresses.

Scope of the Developmental and Epileptic Encephalopathy Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
Base Year: 2021
Developmental and Epileptic Encephalopathy Market CAGR: 15.5%
Developmental and Epileptic Encephalopathy Market Size in 2021: USD 1,371 million

Key Developmental and Epileptic Encephalopathy Companies: Takeda, Eisai, SK Life Science, Stoke Therapeutics, Harmony Biosciences/Epygenix, Longboard Pharmaceuticals, Praxis Precision Medicines, Neurocrine Biosciences, Bright Minds Biosciences, Cerecin, Encoded Therapeutics, Bloom Science, IAMA Therapeutics, Ultragenyx Pharmaceutical, Neuroene Therapeutics, Regel Therapeutics, Jazz Pharmaceuticals, Biocodex, Zogenix (Acquired by UCB), Lundbeck, Marinus Pharmaceuticals, Novartis, Aquestive Therapeutics, Supernus Pharmaceuticals, Eisai Pharmaceuticals, GlaxoSmithKline, Meda Pharmaceuticals, Roche, Mallinckrodt Pharmaceuticals, Xenon Pharmaceuticals, Ovid Therapeutics, BioPharm Solutions and others.

Key Developmental and Epileptic Encephalopathy Therapies: XEN496, Soticlestat, Carisbamate, Carisbamate, EPX-100, NBI-921352, STK-001, NBI-827104, JBPOS0101, PRAX-562, EPX-200 (Lorcaserin), EPX-300, LP352, and others
Therapeutic Assessment: Developmental and Epileptic Encephalopathy current marketed and emerging therapies
Developmental and Epileptic Encephalopathy Market Dynamics: Developmental and Epileptic Encephalopathy market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL’s views, Analyst’s views, Developmental and Epileptic Encephalopathy Market Access and Reimbursement

Discover more about DEE drugsin development @ Developmental and Epileptic Encephalopathy Clinical Trials

Table of Contents

1	Key Insights
2	Developmental and Epileptic Encephalopathy Report Introduction
3	Executive Summary
4	Key Events
5	Developmental and Epileptic Encephalopathy SWOT Analysis
6	Developmental and Epileptic Encephalopathy Epidemiology and Market Methodology
7	Developmental and Epileptic Encephalopathy (DEE) Market Overview at a Glance
7.1	Developmental and Epileptic Encephalopathy Market Share (%) Distribution by Therapies in 2021
7.2	Developmental and Epileptic Encephalopathy Market Share (%) Distribution by Therapies in 2034
8	Developmental and Epileptic Encephalopathy Background and Overview
8.1	West Syndrome
8.2	Dravet Syndrome
8.3	Lennox–Gastaut Syndrome
8.4	Landau–Kleffner Syndrome (LKS) (Acquired Epileptic Aphasia)
8.5	Epilepsy with Continuous Spike-and-Waves during Slow-Wave Sleep
8.6	Doose Syndrome (myoclonic atonic epilepsy)
8.7	CDKL5 deficiency disorder (CDD)
8.8	Tuberous sclerosis complex (TSC)
8.9	Genetic Epilepsy
8.10	Biomarkers of epileptic encephalopathies
9	Treatment of Developmental and Epileptic Encephalopathy
9.1	Antiseizure medications
9.2	Steroid therapy
9.3	Other Therapies
9.4	Epilepsy surgery
9.5	Developmental and Epileptic Encephalopathy Treatment Algorithm
10	Developmental and Epileptic Encephalopathy Treatment Guidelines
11	Developmental and Epileptic Encephalopathy Epidemiology and Patient Population of 7MM
11.1	Key Findings
11.2	Assumptions and Rationale
11.2.1	Dravet Syndrome
11.2.2	Lennox-Gastaut Syndrome
11.2.3	Ohtahara Syndrome
11.2.4	West Syndrome
11.2.5	Landau-Kleffner Syndrome
11.2.6	Tuberous Sclerosis Complex
11.2.7	CDKL5 deficiency disorder
11.2.8	Others
11.3	Diagnosed Prevalent Population of DEE in 7MM
11.4	United States
11.4.1	Diagnosed Prevalent Population of DEE in the United States
11.5	EU-4 and UK
11.5.1	Diagnosed Prevalence of DEE in the EU-4 and the UK
11.6	Japan
11.6.1	Diagnosed Prevalent Population of Developmental and Epileptic Encephalopathy in Japan
12	Marketed Developmental and Epileptic Encephalopathy Drugs
12.1	Key Competitor
13	Emerging Developmental and Epileptic Encephalopathy Drugs
13.1	Key Competitors
14	Developmental and Epileptic Encephalopathy (DEE): 7MM Market Analysis
14.1	Key Findings
14.2	Developmental and Epileptic Encephalopathy Market Outlook
14.3	Key Market Forecast Assumptions
14.4	Attribute Analysis
14.5	Total Market Size of Developmental and Epileptic Encephalopathy in the 7MM
14.6	Developmental and Epileptic Encephalopathy Market Size by Current and Emerging Therapies in the 7MM
14.7	United States Market Size
14.7.1	Total Market Size of DEE in the United States
14.7.2	Market Size of DEE by Current and Emerging Therapies in the United States
14.8	EU-4 and UK Market Size
14.8.1	Total Market size of DEE in the EU-4 and the UK
14.8.2	Market Size of DEE by Current and Emerging Therapies in EU-4 and the UK
14.9	Japan
14.9.1	Total Market size of DEE in Japan
14.9.2	Market Size of DEE by Current and Emerging Therapies in Japan
15	Developmental and Epileptic Encephalopathy Market Drivers
16	Developmental and Epileptic Encephalopathy Market Barriers
17	Developmental and Epileptic Encephalopathy Unmet Needs
18	Developmental and Epileptic Encephalopathy Market Access and Reimbursement
19	Appendix
19.1	Bibliography
19.2	Report Methodology
20	DelveInsight Capabilities
21	Disclaimer
22	About DelveInsight

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Developmental and Epileptic Encephalopathies Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Therapies and Companies by DelveInsight

Vasomotor Symptoms Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Therapies and Companies by DelveInsight

“Vasomotor Symptoms Treatment Market”

Vasomotor Symptoms Companies are Viramal Limited, Simbec Research, Estetra, Mithra Pharmaceuticals, Bayer, Nerre Therapeutics Ltd., Mitsubishi Tanabe Pharma America Inc., MenoGeniX, QUE Oncology, Fervent Pharmaceuticals, and others.

(Albany, USA) DelveInsight’s “Vasomotor Symptoms Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Vasomotor Symptoms, historical and forecasted epidemiology as well as the Vasomotor Symptoms market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The Vasomotor Symptoms market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Vasomotor Symptoms market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Vasomotor Symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Vasomotor Symptoms market.

To Know in detail about the Vasomotor Symptoms market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Vasomotor Symptoms Market Forecast

Some of the key facts of the Vasomotor Symptoms Market Report:

The Vasomotor Symptoms market size is anticipated to grow with a significant CAGR during the study period (2020-2034).
In February 2024, Mithra Pharmaceuticals announced a significant milestone in its clinical research efforts for DONESTA, a hormone therapy utilizing estetrol (E4) to treat moderate to severe vasomotor symptoms (Vasomotor symptoms) associated with menopause. The last patient-out mark was reached in the C301 Endometrial Safety Study, signaling the completion of patient treatments and the initiation of the data management and reporting phase.
As per DelveInsight analysis, the menopause market size in the 7MM was approximately USD 11 billion in 2022.
In the 7MM, the highest number of prevalent cases of vasomotor symptoms was observed in the United States.
According to the assessment done by DelveInsight, the total number of women in menopause in the 7MM comprised approximately 100 million cases in 2022 and are projected to increase during the forecast period.
Key Vasomotor Symptoms Companies: Viramal Limited, Simbec Research, Estetra, Mithra Pharmaceuticals, Bayer, Nerre Therapeutics Ltd., Mitsubishi Tanabe Pharma America Inc., MenoGeniX, QUE Oncology, Fervent Pharmaceuticals, and others
Key Vasomotor Symptoms Therapies: Transdermal Estradiol Cream (VML-0203), DONESTA (E4, Estetrol), Elinzanetant (BAY3427080), MT-8554 (Elismetrep), MNGX-100 (Filgrastim/G-CSF), Q-122 (MSX-122), FP-101, and others
The Vasomotor Symptoms market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Vasomotor Symptoms pipeline products will significantly revolutionize the Vasomotor Symptoms market dynamics.

Vasomotor Symptoms Overview

Vasomotor symptoms (Vasomotor symptoms), commonly associated with menopause, are characterized by hot flashes and night sweats. These symptoms are caused by dysregulation in the hypothalamus, which controls body temperature, and are linked to fluctuating estrogen levels during the menopausal transition. Vasomotor symptom can vary in frequency and intensity, with episodes lasting from seconds to several minutes.

Hot flashes, the hallmark of Vasomotor symptoms, present as sudden waves of heat often accompanied by flushing, sweating, and an increased heart rate. Night sweats, their nocturnal counterpart, can disrupt sleep, leading to fatigue and diminished quality of life. Although most common during menopause, Vasomotor symptoms may also occur in other situations, such as following oophorectomy or cancer treatments that affect hormonal balance.

The prevalence of Vasomotor symptoms varies globally, influenced by genetics, lifestyle, and cultural factors. While Vasomotor symptoms typically decline within a few years post-menopause, some women experience symptoms for a decade or longer. Management strategies include lifestyle modifications, hormone replacement therapy (HRT), and non-hormonal treatments like selective serotonin reuptake inhibitors (SSRIs) and cognitive behavioral therapy (CBT). Emerging therapies, such as neurokinin receptor antagonists, offer promising alternatives for women seeking relief from Vasomotor symptoms. Early intervention and tailored treatments can significantly enhance patient well-being.

Request for sample report @ Vasomotor Symptoms Treatment Market

Vasomotor Symptoms Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

DelveInsight estimates that there were approximately 100 million total women in menopause in the 7MM in 2022.

For the age-specific analysis, the number of cases of menopause were distributed across various age groups, such as

Vasomotor Symptoms Epidemiology Segmentation:

The Vasomotor Symptoms market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Number of Women in Menopause
Stage-Specific Distribution of Women in Menopause
Age-Specific Distribution of Women in Menopause
Number of Women in Menopause with Vasomotor Symptoms
Number of Women in Menopause with Moderate-to-Severe Vasomotor Symptoms

Download the report to understand which factors are driving Vasomotor Symptoms epidemiology trends @ Vasomotor Symptoms Epidemiology Forecast

Vasomotor Symptoms Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Vasomotor Symptoms market or expected to get launched during the study period. The analysis covers Vasomotor Symptoms market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Vasomotor Symptoms Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Vasomotor Symptoms Therapies and Key Companies

Transdermal Estradiol Cream (VML-0203): Viramal Limited/Simbec Research
DONESTA (E4, Estetrol): Estetra/Mithra Pharmaceuticals
Elinzanetant (BAY3427080): Bayer|Nerre Therapeutics Ltd.
MT-8554 (Elismetrep): Mitsubishi Tanabe Pharma America Inc.
MNGX-100 (Filgrastim/G-CSF): MenoGeniX
Q-122 (MSX-122): QUE Oncology
FP-101: Fervent Pharmaceuticals

Discover more about therapies set to grab major Vasomotor Symptoms market share @ Vasomotor Symptoms Drugs Market

Vasomotor Symptoms Treatment Market

The North American Menopause Society (NAMS) advises waiting until hot flashes become bothersome before seeking treatment. Treatment initiation should consider the severity of symptoms, evaluation of treatment risks, and the woman’s perspective on menopause and medication. Duavee (bazedoxifene acetate/conjugated estrogens) is the initial and sole medication combining CE with an estrogen agonist/antagonist, recognized as a selective estrogen receptor modulator (SERM), for menopausal Vasomotor symptoms treatment. Duavee incorporates bazedoxifene instead of progestin to safeguard the uterine lining against hyperplasia, a potential consequence of estrogen-only therapy.

Numerous women opt for non-prescription therapies like isoflavones, black cohosh, and progesterone-containing hormone creams to manage conditions like hot flashes. However, clinical evidence regarding the efficacy and long-term safety of these therapies remains inadequate. Moreover, most over-the-counter remedies for hot flashes are classified as dietary supplements and hence not regulated by the US Food and Drug Administration. Prescription medications with demonstrated efficacy in alleviating hot flashes are available for women unable to undergo hormone therapy. Certain prescription antidepressants, including those suitable for women with a history of breast cancer, may diminish hot flashes. Others include gabapentin, clonidine, and methyldopa. NAMS suggests that women experiencing mild menopause-related hot flashes initially consider lifestyle modifications such as adjusting environmental conditions for cooler core body temperatures, engaging in regular exercise, quitting smoking, and employing relaxation techniques such as paced respiration.

Vasomotor Symptoms Market Dynamics

The dynamics of the menopause market are experiencing notable changes due to the increasing societal awareness of women’s health and well-being. With a growing aging population and a heightened focus on women’s empowerment, there’s a rising demand for innovative products and services that address the physical and emotional difficulties associated with menopause. This surge in demand has led to increased research and development efforts, resulting in a diverse array of hormone replacement therapies, herbal supplements, lifestyle applications, and personalized health strategies.

As more women seek comprehensive and effective solutions, companies are adopting a more consumer-centric approach, tailoring their offerings to individual preferences and needs. Moreover, discussions surrounding menopause are becoming less taboo, fostering open dialogue and knowledge-sharing, which further shapes the dynamics of the menopause market by creating a supportive environment for women navigating this stage of life.

However, despite the potential for growth, the menopause market faces several barriers. Strict regulatory processes governing hormonal treatments and supplements, alongside concerns regarding product safety and effectiveness, present challenges for new entrants into the menopause market. Additionally, cultural stigmas and misinformation surrounding menopause persist in certain societies, hindering open conversations and the adoption of innovative solutions. Economic disparities and limited access to healthcare exacerbate these challenges, impeding equal penetration of the menopause market. Overcoming these barriers necessitates a multifaceted approach involving education, regulatory reforms, and inclusive product development to fully harness the potential of the menopause market.

Request for sample report to know more about therapies and drugs @ Vasomotor Symptoms Clinical Trials and Advancements

Scope of the Vasomotor Symptoms Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Vasomotor Symptoms Companies: Viramal Limited, Simbec Research, Estetra, Mithra Pharmaceuticals, Bayer, Nerre Therapeutics Ltd., Mitsubishi Tanabe Pharma America Inc., MenoGeniX, QUE Oncology, Fervent Pharmaceuticals, and others
Key Vasomotor Symptoms Therapies: Transdermal Estradiol Cream (VML-0203), DONESTA (E4, Estetrol), Elinzanetant (BAY3427080), MT-8554 (Elismetrep), MNGX-100 (Filgrastim/G-CSF), Q-122 (MSX-122), FP-101, and others
Vasomotor Symptoms Therapeutic Assessment: Vasomotor Symptoms current marketed and Vasomotor Symptoms emerging therapies
Vasomotor Symptoms Market Dynamics: Vasomotor Symptoms market drivers and Vasomotor Symptoms market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Vasomotor Symptoms Unmet Needs, KOL’s views, Analyst’s views, Vasomotor Symptoms Market Access and Reimbursement

Table of Contents

1. Vasomotor Symptoms Market Report Introduction

2. Executive Summary for Vasomotor Symptoms

3. SWOT analysis of Vasomotor Symptoms

4. Vasomotor Symptoms Patient Share (%) Overview at a Glance

5. Vasomotor Symptoms Market Overview at a Glance

6. Vasomotor Symptoms Disease Background and Overview

7. Vasomotor Symptoms Epidemiology and Patient Population

8. Country-Specific Patient Population of Vasomotor Symptoms

9. Vasomotor Symptoms Current Treatment and Medical Practices

10. Vasomotor Symptoms Unmet Needs

11. Vasomotor Symptoms Emerging Therapies

12. Vasomotor Symptoms Market Outlook

13. Country-Wise Vasomotor Symptoms Market Analysis (2020–2034)

14. Vasomotor Symptoms Market Access and Reimbursement of Therapies

15. Vasomotor Symptoms Market Drivers

16. Vasomotor Symptoms Market Barriers

17. Vasomotor Symptoms Appendix

18. Vasomotor Symptoms Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Vasomotor Symptoms Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Therapies and Companies by DelveInsight

Bullous Pemphigoid Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Therapies and Companies by DelveInsight

“Bullous Pemphigoid Treatment Market”

Key Bullous Pemphigoid Companies are AstraZeneca, Kyowa Kirin, Regeneron,Sanofi, Argenx, Innate Pharma, ARTham Therapeutics, Kaken Pharmaceutical, Mayo Clinic, Nihon Pharmaceutical Co., Ltd, Immune Pharmaceuticals, AKARI Therapeutics and others.

[Albany, United States] – DelveInsight’s “Bullous Pemphigoid Market Insights, Epidemiology, and Market Forecast 2034” report offers a detailed examination of Bullous Pemphigoid, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

The Bullous Pemphigoid market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as AstraZeneca, Kyowa Kirin, Regeneron,Sanofi, Argenx, Innate Pharma, ARTham Therapeutics, Kaken Pharmaceutical, Mayo Clinic, Nihon Pharmaceutical Co., Ltd, Immune Pharmaceuticals, AKARI Therapeutics and others.

To Know in detail about the Bullous Pemphigoid Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here: Bullous Pemphigoid Market Report

Key Findings from the Bullous Pemphigoid Market Report:

The Bullous Pemphigoid market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2020-2034).
In September, 2024: Regeneron Pharmaceuticals announced that the maine purpose of their study is to investigate whether dupilumab is effective and safe for the treatment of bullous pemphigoid. Dupilumab is a type of drug called a “monoclonal antibody”. An antibody is a special kind of protein that the immune (defense) system normally makes to fight bacteria and viruses.
In July, 2024: Investigación Sanitaria de la Fundación Jiménez Díaz announced that a phase IIa, open label, non controlled clinical trial to assess the feasibility and safety of allogeneic adipose-derived mesenchymal stem cells (ASC) in the treatment of cicatricial conjunctivitis associated with Lyell’s syndrome, Stevens-Johnson’s syndrome and mucous membrane pemphigoid with ocular involvement
In January, 2024: argenx announced that ARGX-113-2009 is an operationally seamless 2-part, phase 2/3, prospective, global, multicenter, randomized, double-blinded, placebo-controlled study to investigate the efficacy, safety, tolerability, immunogenicity, participant-reported outcome measures (including those assessing participant QoL), PK, and PD of efgartigimod PH20 SC administered via subcutaneous (SC) injection in adult participants with moderate to severe BP.
According to the recent cross-sectional analysis conducted Wertenteil et al. (2018), titled “Prevalence estimates for pemphigoid in the US: A sex-adjusted an age-adjusted population analysis” the overall prevalence of pemphigoid was 0.012%, or 12 pemphigoid patients/100,000 adults in the US.
According to the study conducted by Persson et al. (2020), in the UK, the prevalence of BP was 26.82 (95% CI 23.83-30.19) per 100,000 people in 1998 and increased to 47.99 (95% CI 43.09-53.46) per 100,000 in 2017.
According to “Japan Intractable diseases,” approximately 6,850 patients with pemphigoid, including both bullous and non bullous pemphigoid, with the majority considered to be the elderly.
Key Bullous Pemphigoid Companies are as follows: AstraZeneca, Kyowa Kirin, Regeneron,Sanofi, Argenx, Innate Pharma, ARTham Therapeutics, Kaken Pharmaceutical, Mayo Clinic, Nihon Pharmaceutical Co., Ltd, Immune Pharmaceuticals, AKARI Therapeutics
Key Bullous Pemphigoid Therapies are as follow: DUPIXENT (dupilumab), Kenketu Glovenin-I (NPB-01), VYVGART (efgartigimod PH20 SC), Ixekizumab, Prednisone, dupilumab, NPB-01, Bertilimumab, rVA576
Launching multiple stage Bullous Pemphigoid pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Bullous Pemphigoid market research report to uncover actionable insights, industry forecasts, and competitive analysis @ Bullous Pemphigoid Treatment Market

Bullous Pemphigoid Overview:

Bullous pemphigoid (BP) is a chronic autoimmune blistering disorder that primarily affects the elderly, typically over 60 years of age. It is caused by autoantibodies targeting hemidesmosomal proteins, particularly BP180 and BP230, which are essential for epidermal-dermal adhesion. The resulting immune response leads to subepidermal blister formation.

Bullous pemphigoid often presents with pruritic, tense blisters on normal or erythematous skin, predominantly on the trunk, limbs, and flexural areas. Early stages may resemble eczema or urticaria, making diagnosis challenging. Mucosal involvement is less common compared to other autoimmune blistering diseases, such as pemphigus vulgaris.

Bullous pemphigoid Diagnosis is confirmed through a combination of clinical findings, histopathology, direct immunofluorescence (showing linear IgG and C3 deposition along the basement membrane), and serological tests detecting circulating autoantibodies.

Bullous pemphigoid Treatment aims to control inflammation and prevent blister formation. First-line therapy includes high-potency topical corticosteroids or systemic corticosteroids for severe cases. Immunosuppressive agents like azathioprine or mycophenolate mofetil and biologics, such as rituximab, are considered in refractory cases. Nonsteroidal treatments, including doxycycline, are also effective with fewer side effects.

Although Bullous pemphigoid can significantly impact quality of life, prompt diagnosis and appropriate management often lead to remission, reducing morbidity and improving patient outcomes.

Bullous Pemphigoid Epidemiology Segmentation:

The Bullous Pemphigoid market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

Bullous Pemphigoid Diagnosed prevalent
Bullous Pemphigoid Gender-specific diagnosed prevalent cases
Bullous Pemphigoid Age-specific diagnosed prevalent cases
Bullous Pemphigoid Diagnosed Total treated cases

For more information about Bullous Pemphigoid companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/bullous-pemphigoid-market

Bullous Pemphigoid Market Insights

Bullous pemphigoid is an uncommon autoimmune subepidermal blistering disease that accounts for about 70% of subepidermal bullous diseases, mainly affecting the elderly.

Treatment of Bullous pemphigoid aims to arrest the development of new lesions and enable cutaneous healing and control of pruritus. As Bullous pemphigoid mainly affects elderly individuals, the choice of therapy has to be tailored according to the patient’s comorbidities and ability to self care to avoid potential complications and increased morbidity and mortality.

Currently there is no FDA approved therapy for Bullous pemphigoid in the 7MM, but pharmaceutical companies are constantly working to bring innovative treatments soon into the market which could meet the unmet demands of Bullous pemphigoid patients. efgartigimod, developed argenx, and dupilumab developed by Regeneron/Sanofi are in the Phase III clinical development.

Bullous Pemphigoid Drugs Uptake

FASENRA (benralizumab) is a monoclonal antibody that binds directly to IL-5 receptor alpha on eosinophils. It attracts natural killer (NK) cells to induce rapid and near-complete depletion of blood and tissue eosinophils in most patients via apoptosis (programmed cell death).
DUPIXENT (dupilumab) is a monoclonal antibody targeting the chain of the interleukin (IL)-4 receptor. It inhibits the biological effects of the cytokines IL-4 and IL-13, which are key drivers in the TH2 response.
VYVGART (efgartigimod PH20 SC) developed by Argenx is an antibody fragment designed to reduce pathogenic immunoglobulin G (IgG) antibodies by binding to the neonatal Fc receptor and blocking the IgG recycling process.

Bullous Pemphigoid Therapies and Key Companies:

DUPIXENT (dupilumab): Regeneron/ Sanofi
Kenketu Glovenin-I (NPB-01): Nihon Pharmaceutical/ Takeda
VYVGART (efgartigimod PH20 SC): Argenx
Ixekizumab: Mayo Clinic
Prednisone: argenx
dupilumab: Regeneron Pharmaceuticals
NPB-01: Nihon Pharmaceutical Co., Ltd
Bertilimumab: Immune Pharmaceuticals
rVA576: AKARI Therapeutics

Bullous Pemphigoid Epidemiology:

Bullous pemphigoid is considered a rare disease, with its incidence estimated at 2.5-42.8 cases per million annually, depending on the region. Studies show that the prevalence of BP is higher in Europe and North America compared to other parts of the world. However, the condition is becoming more recognized, and the incidence is rising due to better diagnostic tools and increasing awareness.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ Bullous Pemphigoid Companies and Medication

Bullous Pemphigoid Market Drivers:

Rising Incidence in Aging Population
Advances in Immunotherapy and Targeted Therapies
Increased Awareness and Early Diagnosis
Development of Novel Therapeutics and Pipeline Drugs

Bullous Pemphigoid Market Barriers:

Limited Awareness and Misdiagnosis
Adverse Side Effects of Existing Treatments
Regulatory Challenges and Slow Approvals
Limited Patient Pool

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ Bullous Pemphigoid Clinical trials and Advancements

Scope of the Bullous Pemphigoid Market Report:

Study Period: 2020-2034
Coverage: 7MM (The United States, EU5, and Japan)
Key Bullous Pemphigoid Companies: AstraZeneca, Kyowa Kirin, Regeneron,Sanofi, Argenx, Innate Pharma, ARTham Therapeutics, Kaken Pharmaceutical, Mayo Clinic, Nihon Pharmaceutical Co., Ltd, Immune Pharmaceuticals, AKARI Therapeutics
Key Bullous Pemphigoid Therapies: DUPIXENT (dupilumab), Kenketu Glovenin-I (NPB-01), VYVGART (efgartigimod PH20 SC), Ixekizumab, Prednisone, dupilumab, NPB-01, Bertilimumab, rVA576
Bullous Pemphigoid Therapeutic Assessment: Current marketed and emerging therapies
Bullous Pemphigoid Market Dynamics: Bullous Pemphigoid Market drivers and Bullous Pemphigoid barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Bullous Pemphigoid Unmet Needs: Insights into unmet needs, KOL’s views, Analyst’s views, Market Access, and Reimbursement.

Table of Content:

1 Key Insights

2 Report Introduction

3 Bullous Pemphigoid Market Overview at a Glance

4 Executive Summary of Bullous Pemphigoid

5 Epidemiology and Market Methodology

6 Disease Background and Overview

7 Diagnosis of Bullous Pemphigoid

8 Treatment and Management

9 Conclusion

10 Epidemiology and Patient Population

11 Patient Journey

12 Key Endpoints in Bullous Pemphigoid clinical trials

13 Marketed Therapies

14 Emerging Therapies

15 Bullous Pemphigoid: The 7MM Analysis

16 KOL Views

17 SWOT Analysis

18 Unmet Needs

19 Appendix

20 DelveInsight Capabilities

21 Disclaimer

22 About DelveInsight

About DelveInsight:

DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Bullous Pemphigoid Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Therapies and Companies by DelveInsight

Glioblastoma Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Therapies and Companies by DelveInsight

“Glioblastoma Treatment Market”

Glioblastoma Companies are Bayer, Chimerix, Aivita Biomedical, Denovo Biopharma, Northwest Therapeutics, VBL Therapeutics, Laminar Pharmaceuticals, MedImmune, DNAtrix, Immunomic Therapeutics, Imvax, MimiVax, CNS Pharmaceuticals, Epitopoietic Research Corporation (ERC), Istari Oncology, Kintara Therapeutics, Bristol Myers Squibb, Medicenna Therapeutics, BioMimetix, Eisai, Merck, Kazia Therapeutics, Oblato, Genenta Science, Enterome, Inovio Pharmaceuticals, VBI Vaccines, and TME Pharma, and others

(Albany, USA) DelveInsight’s “Glioblastoma Market Insights, Epidemiology and Market Forecast– 2034” report delivers an in-depth understanding of the Glioblastoma, historical and forecasted epidemiology as well as the Glioblastoma market trends in the United States, the EU-4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

The Glioblastoma market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Glioblastoma market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Glioblastoma treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Glioblastoma market.

Key Takeaways from the Glioblastoma Market Report

The increase in Glioblastoma Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
As per DelveInsight analysis, the Glioblastoma Market is anticipated to witness growth at a considerable CAGR.

The leading Glioblastoma Companies working in the market include Bayer, Chimerix, Aivita Biomedical, Denovo Biopharma, Northwest Therapeutics, VBL Therapeutics, Laminar Pharmaceuticals, MedImmune, DNAtrix, Immunomic Therapeutics, Imvax, MimiVax, CNS Pharmaceuticals, Epitopoietic Research Corporation (ERC), Istari Oncology, SonALAsense, Kintara Therapeutics, Bristol Myers Squibb, Medicenna Therapeutics, BioMimetix, Eisai, Merck Sharp & Dohme, Kazia Therapeutics, Oblato, Genenta Science, Enterome, Inovio Pharmaceuticals, Karyopharm Therapeutics, Forma Therapeutics, VBI Vaccines, and TME Pharma, and others.

Promising Glioblastoma Pipeline Therapies in the various stages of development include ITI-1000 (pp65 DC Vaccine), VBI-1901, Selinexor (KPT-330), Trans Sodium Crocetinate, Ofranergene obadenovec (VB-111), Temodar/Temodal, Avastin, Azeliragon, PLX3397, Temozolomide, VXM01, Avelumab, and others.
On October 15, 2024, the FDA granted Fast Track designation to LP-184, a small-molecule alkylating agent developed by Lantern Pharma for the treatment of glioblastoma (GBM). LP-184 induces tumor cell death through DNA damage and is currently in a Phase 1a trial assessing its safety and tolerability in patients with various solid tumors, including GBM. The Fast Track status aims to accelerate the development and review of LP-184, particularly given the limited treatment options for aggressive brain cancers like GBM.
April 2024:- Boston Scientific Corporation- FRONTIER: A Feasibility Study to Evaluate the Safety of the TheRaSphere GliOblastoma (GBM) Device iN PaTIEnts With Recurrent GBM. Glioblastoma (GBM) is a highly aggressive brain cancer with a grave prognosis, resulting in <7% of patients surviving to five years post-diagnosis. External beam radiotherapy (EBRT) is currently a mainstay treatment for GBM; however, the dose delivered is limited by side effects. The targeted radiotherapy of the TheraSphere GBM Y-90 Glass Microsphere System (TheraSphere GBM) has promising potential to provide GBM patients with reduced side effects compared to external beam radiotherapy as well as a more effective treatment for this catastrophic disease.
April 2024:- TJ Biopharma Co., Ltd. – A Phase 2, Randomized, Single-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT). A Phase 2, Randomized, Single-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients with Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT).

Discover which therapies are expected to grab the Glioblastoma Market Share @ Glioblastoma Market Outlook

Glioblastoma Overview

Glioblastoma (GBM) is an aggressive and the most common primary malignant brain tumor in adults. Classified as a grade IV astrocytoma by the World Health Organization, it originates from astrocytes, the supportive glial cells in the brain. GBM is characterized by rapid growth, extensive infiltration into surrounding brain tissue, and significant heterogeneity at the cellular and molecular levels.

Patients often present with neurological symptoms such as headaches, seizures, cognitive decline, or focal deficits, depending on the tumor’s location. Diagnosis typically involves magnetic resonance imaging (MRI) and confirmation via biopsy or surgical resection, which also serves as an initial treatment step.

Standard treatment includes maximal safe surgical resection, followed by concurrent radiotherapy and temozolomide chemotherapy. Despite aggressive multimodal therapy, GBM remains highly resistant to treatment, with a median survival of 15–18 months. Recurrence is almost inevitable, and treatment options for recurrent disease are limited.

Molecular profiling of GBM, including markers like MGMT promoter methylation and IDH mutation status, guides prognosis and treatment decisions. Emerging therapies, such as tumor-treating fields (TTFs), immunotherapy, and targeted molecular inhibitors, are under investigation. While these advances offer hope, GBM remains a formidable challenge, highlighting the urgent need for innovative therapies.

Glioblastoma Epidemiology Insights

The epidemiology section of Glioblastoma offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

Download the report to understand which factors are driving Glioblastoma Epidemiology trends @ Glioblastoma Epidemiological Insights

Glioblastoma Drugs Market

The Glioblastoma Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Glioblastoma signaling in Glioblastoma are likely to uncover new therapeutic targets and further expand treatment options for patients.

Glioblastoma Treatment Market Landscape

The Glioblastoma treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Glioblastoma has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

To know more about Glioblastoma treatment guidelines, visit @ Glioblastoma Treatment Market Landscape

Glioblastoma Market Outlook

The report’s outlook on the Glioblastoma market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Glioblastoma therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Glioblastoma drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Glioblastoma market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.

Glioblastoma Drugs Uptake

The drug chapter of the Glioblastoma report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Glioblastoma.

Major Glioblastoma Companies

Several Glioblastoma Companies working in the market include Bayer, Chimerix, Aivita Biomedical, Denovo Biopharma, Northwest Therapeutics, VBL Therapeutics, Laminar Pharmaceuticals, MedImmune, DNAtrix, Immunomic Therapeutics, Imvax, MimiVax, CNS Pharmaceuticals, Epitopoietic Research Corporation (ERC), Istari Oncology, SonALAsense, Kintara Therapeutics, Bristol Myers Squibb, Medicenna Therapeutics, BioMimetix, Eisai, Merck Sharp & Dohme, Kazia Therapeutics, Oblato, Genenta Science, Enterome, Inovio Pharmaceuticals, Karyopharm Therapeutics, Forma Therapeutics, VBI Vaccines, and TME Pharma, and others.

Learn more about the FDA-approved drugs for Glioblastoma @ Drugs for Glioblastoma Treatment

Scope of the Glioblastoma Market Research Report

Coverage- 7MM

Glioblastoma Companies- Bayer, Chimerix, Aivita Biomedical, Denovo Biopharma, Northwest Therapeutics, VBL Therapeutics, Laminar Pharmaceuticals, MedImmune, DNAtrix, Immunomic Therapeutics, Imvax, MimiVax, CNS Pharmaceuticals, Epitopoietic Research Corporation (ERC), Istari Oncology, SonALAsense, Kintara Therapeutics, Bristol Myers Squibb, Medicenna Therapeutics, BioMimetix, Eisai, Merck Sharp & Dohme, Kazia Therapeutics, Oblato, Genenta Science, Enterome, Inovio Pharmaceuticals, Karyopharm Therapeutics, Forma Therapeutics, VBI Vaccines, and TME Pharma, and others.
Glioblastoma Pipeline Therapies- ITI-1000 (pp65 DC Vaccine), VBI-1901, Selinexor (KPT-330), Trans Sodium Crocetinate, Ofranergene obadenovec (VB-111), Temodar/Temodal, Avastin, Azeliragon, PLX3397, Temozolomide, VXM01, Avelumab, and others.
Glioblastoma Market Dynamics: Glioblastoma Market Drivers and Barriers
Glioblastoma Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Glioblastoma Drugs in development @ Glioblastoma Clinical Trials and Advancements

Table of Content

1. Key Insights

2. Report Introduction

3. Glioblastoma Multiforme Market Overview at a Glance

4. Epidemiology and Market Forecast Methodology

5. Executive Summary of Glioblastoma Multiforme (GBM)

6. Key Events

7. Glioblastoma SWOT Analysis

8. Disease Background and Overview: Glioblastoma Multiforme

9. Glioblastoma Treatment

10. Guidelines and Recommendations from Different Organizations

11. Glioblastoma Epidemiology and Patient Population

12. Glioblastoma Patient Journey

13. Key Endpoints in Glioblastoma Multiforme

14. Glioblastoma Marketed Products

15. Emerging Glioblastoma Drugs

16. Glioblastoma Market: Seven Major Market Analysis

17. Glioblastoma KOL Views

18. Glioblastoma Unmet Needs

19. Glioblastoma Market Access and Reimbursement

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Glioblastoma Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Therapies and Companies by DelveInsight

Agreement for $27 Million in Funding for Expanding Clinic Acquisitions and Operations, Plus New Drug Application for Treatment of Suicidal Depression: NRx Pharmaceuticals, Inc. Stock Symbol: NRXP

Developing NRX-101, an FDA-Designated Investigational Breakthrough Therapy for Suicidal Treatment-Resistant Bipolar Depression and Chronic Pain.

Aiming to be the First FDA-Approved Medication to Treat Suicidal Depression

Designed to Help Address the Needs of Over 13 Million Americans who Seriously Consider Suicide Each Year (CDC).

Binding Term Sheet for $27 Million in Funding for HOPE Clinic Acquisitions and Pharmaceutical Operations

Kadima Neuropsychiatry Institute Targeted as First Acquisition for HOPE Subsidiary International Network of Interventional Psychiatry Clinics.

Kadima is a Leading Investigative Site for CNS and Psychedelic Research.

Completion of NDA Filing Expected in First Quarter of 2025

Plans to Participate in January J.P. Morgan Healthcare Conference.

NRXP given a $31 Price Target from Respected Investment Analyst D. Boral Capital

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain

NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

Intravenous ketamine is widely accepted as a standard of care for acute treatment of suicidal depression, in the absence of an FDA-labeled product; the only treatment currently approved by the FDA is electroconvulsive therapy (ECT). According to the CDC, 3.8 million Americans make a plan for suicide each year. This represents a $3-5 billion market at expected pricing. Based on the data in the trials referenced above, the Company’s regulatory counsel encouraged the Company to file an NDA for suicidal depression for NRX-100.

In a January 2025 report, respected investment analysis firm D. Boral Capital assigned NRXP a $31 Price Target. The full report may be viewed at this link: https://www.nrxpharma.com/wp-content/uploads/2025/01/HOPE-Therapeutics-Advances-With-Kadima.pdf.

The new D. Boral valuation includes the following commentary: Our $31 PT is based on the success of NRX-100 and NRX-101, including revenues from the clinic acquisitions (Hope Therapeutics). Our valuation models include Free Cash Flow to the Firm (FCFF), disc EPS (dEPS), and Sum-of-the-Parts (SOP). We use a 30% disc rate. This is in addition to our revenue models’ 30% risk cut or 70% Probability of Success POS factor. We select 30% for micro-capitalized growth co’s, representing our highest risk rate. These three models’ results are equal-weighted, averaged, and rounded to the nearest whole number to provide a 12-month PT.

Binding Term Sheet for $27 Million in Funding for HOPE Clinic Acquisitions and Pharmaceutical Operations

On January 6th NRXP announced signing of a Binding Term Sheet with Smith & Sauer, LLC, for $25 million equity purchases to fund planned HOPE clinic subsidiary acquisitions. Company management anticipates this new capital in combination with anticipated bank and/or bond lending to be sufficient to drive substantial revenue in HOPE clinic acquisition during 2025, as recently forecast by independent securities analysts. An additional $2 million equity investment in NRXP will be used to advance the Company’s new drug applications for NRX-100 and NRX-101.

Benefits of this agreement include:

Anticipated capital from funds managed by Smith & Sauer to augment potential bank-financing for acquisition of HOPE Therapeutics clinics and support NRXP operations.

Purchase of $25 million in Series A Preferred Stock in HOPE Therapeutics (non-dilutive to NRXP shareholders) convertible into 1/3 of fully diluted HOPE Therapeutics equity, with a 15% current preferred dividend (non-callable for 2 years) for planned HOPE clinic acquisitions.

Purchase $2 million in NRXP equity, above the most recent closing price, at $2.75 per share. Investor will also purchase 500,000 NRXP shares from existing shareholders for $2.75 per share

In connection with both investments, investor shall receive warrants to purchase 3 million currently unregistered shares of NRXP common stock at $3.00 per share with a 24-month term.

Smith & Sauer will also be entitled to receive royalties on net revenues from NRXP product sales to a defined rate of return

Investment in HOPE Therapeutics is expected to enhance the NRXP balance sheet value, strengthening its financial position.

Smith & Sauer to join the HOPE Therapeutics and NRx Pharmaceuticals’ Boards of Directors

Kadima Neuropsychiatry Institute Expected First Acquisition for HOPE Subsidiary International Network of Interventional Psychiatry Clinics

On January 2nd NRXP announced the planned acquisition of the Kadima Neuropsychiatry Institute of La Jolla, CA, per the previously announced Letter of Intent, for the Company’s HOPE subsidiary network. Kadima is expected to serve as the flagship clinic for HOPE’s planned international network of interventional psychiatry clinics, designed to provide advanced treatments for debilitating diseases such as depression, anxiety and PTSD.

Kadima is one of the world’s premier interventional psychiatry clinics and was among the first to introduce Ketamine Therapy for Central Nervous System (CNS) disorders at scale in the clinic setting. The clinic offers a full range of cutting-edge treatments for suicidal depression, anxiety, Post Traumatic Stress Disorder (PTSD) and other CNS disorders. Those treatment options include Ketamine Therapy, Spravato® (nasal esketamine), Transcranial Magnetic Stimulation as well as medication management.

Kadima also has a robust research division and is a leading investigative site for innovative CNS treatments, specializing in psychedelic research, for which it has served as a leading site in nearly all major clinical trials in this area. Kadima has contracts in place with the US Department of Veterans Affairs and also treats active-duty military personnel in the US Department of Defense under Tricare and other treatment programs.

Kadima’s founder and CEO, Prof. David Feifel, MD PHD, has been a pioneer and international thought leader for advanced interventional treatment of psychiatric disorders such as depression, anxiety, PTSD and related disorders for more than three decades.

Upon consummation of the acquisition, Dr. Feifel will serve as NRXP HOPE’s Chief Medical Innovation Officer (CMIO), focused on identifying and evaluating new developments in the treatment of CNS disorders and insuring Hope clinics are at the forefront of interventional psychiatry delivery, and leading global clinical trials to continue to advance the ability to treat these lethal diseases.

Dr. Feifel will join NRXP Chairman, Prof. Jonathan Javitt in presenting a Keynote address at the 8th Annual Neuroscience Innovation Forum during the JP Morgan Healthcare Conference in San Francisco, CA on the 12th of January 2025, and will join in meeting investors over the following week.

Initial Section of U.S. New Drug Application to the FDA for NRX-100 (IV Ketamine) for the Treatment of Suicidal Depression

On December 30th NRXP announced the transmission of first section of its New Drug Application (NDA) for NRX-100 (ketamine) for electronic filing with the U.S. Food & Drug Administration (FDA). NRX-100 was initially granted Fast Track Designation in 2017 for use in combination with NRX-101 (D-cycloserine/lurasidone) for treatment of suicidal bipolar depression. The Company is now seeking to expand the indication to include Suicidal Ideation in Major Depressive Disorder and other forms of depression, based on data from NIH- and European Government-funded trials that have been summarized on the NRXP website.

For more information on $NRXP visit: https://www.nrxpharma.com/ and https://compasslivemedia.com/case-study/nrx-pharmaceuticals/

DISCLAIMER: https://corporateads.com/disclaimer/

Disclosure listed on the CorporateAds website

Media Contact
Company Name: NRx Pharmaceuticals, Inc.
Contact Person: Matthew Duffy, Chief Business Officer
Email: Send Email
Phone: 484 254 6134
Address:1201 Orange Street Suite 600
City: Miami
State: Florida
Country: United States
Website: https://www.nrxpharma.com/

BW-100: The Next Evolution in Electronic Maintenance – Non-Flammable, Eco-Friendly, and High-Performance

BEX USA introduces BW-100 Electronic Contact Cleaner, a revolutionary product poised to redefine how sensitive electronics are maintained. Featuring cutting-edge technology, unmatched safety, and environmentally friendly design, BW-100 sets a new benchmark in electronic cleaning solutions for professionals, hobbyists, gamers and everyday users alike.

A Technological Leap in Electronic Cleaning

BW-100 leverages the latest advancements in chemical engineering to address critical challenges in electronic maintenance. Traditional cleaners often pose risks due to flammability or leave residues that compromise performance. BW-100 eliminates these concerns with its non-flammable formula and residue-free application, ensuring seamless functionality for even the most delicate components.

Key Features that Redefine Performance:

– Non-Flammable Technology: Engineered for absolute safety, BW-100 removes the risks associated with traditional contact cleaners, making it ideal for sensitive electronics.

– Eco-Friendly Innovation: Powered by HFO-1233ZD, a cutting-edge halogenated solvent with zero ozone depletion potential and an exceptionally low global warming impact, BW-100 aligns with sustainability goals without compromising efficiency.

– Quick and Residue-Free Cleaning: Removes oil, grease, and dust effortlessly, restoring electronic devices to peak performance without leaving behind any sticky residues.

– Universal Application: Compatible with rubber, metal, and most plastics, BW-100 is versatile enough to clean gaming consoles, audio equipment, automotive electronics, and more.

A Solution for Modern Technology Enthusiasts

Whether a gamer tackling joystick drift, an audio technician maintaining precision equipment, or a tech enthusiast extending the life of vintage devices, BW-100 provides the perfect solution. Its innovative formulation makes it a must-have for those who demand safe, effective, and eco-friendly maintenance tools.

A Proven Favorite on Amazon

BW-100 has already garnered widespread acclaim on Amazon, where customers praise its efficiency and safety. With an average rating of 4.6 out of 5 stars, users highlight its ability to clean sensitive electronics with ease and reliability. One review reads:

“This stuff is amazing! It completely cleaned my gaming controllers, and now they work like new!” BW-100 is available now in various sizes and configurations:

https://www.amazon.com/BW-100-Nonflammable-Electronic-Contact-Upsidedown/dp/B07FNBW4 7M

Why Tech Innovators Should Take Note

BW-100 represents more than just a product—it’s a commitment to advancing how BEX USA care for the devices that power peoples lives. With its environmentally conscious formula and user-first design, it’s a natural fit for tech-forward audiences seeking tools that align with modern values of innovation and sustainability.

About BEX USA

BEX USA proudly presents BW-100, a breakthrough electronic contact cleaner that sets a new standard for safe, efficient, and environmentally friendly electronic maintenance. Designed for professionals, hobbyists, and everyday consumers, BW-100 provides a highly effective, non-flammable solution for keeping electronics clean and functional.

Media Contact
Company Name: BEX USA
Contact Person: Junseo (Kevin) Lee – Overseas Strategy Team Manager
Email: Send Email
Country: United States
Website: https://www.amazon.com/stores/BW-100/page/2C0C4609-88F8-4FC3-9E30-D711A0254FDB

Pro Painting & More Expands Services to Battlefield Area with Expert Interior and Exterior Painting Solutions

Pro Painting & More, a leading painting service provider, has announced the expansion of its professional painting services to the Battlefield area, bringing top-quality interior and exterior painting expertise to homeowners and businesses alike.

With a reputation for exceptional craftsmanship and attention to detail, Pro Painting & More aims to meet the growing demand for reliable painting services in the region. The company specializes in both interior home painters Battlefield and exterior painters Battlefield, ensuring every surface is transformed to perfection. Their skilled team is dedicated to providing seamless, long-lasting results for various painting projects. They also offer free estimates and personalized consultations to help clients choose the best options for their needs and budgets.

One of the standout services Pro Painting & More offers is kitchen cabinet refinishing and painting. Homeowners looking to refresh their kitchens can turn to the kitchen cabinet painters Battlefield experts who bring years of experience and a passion for reviving outdated cabinetry. Whether a complete makeover or a simple refresh, the team offers customized solutions to meet each client’s needs. The company prides itself on providing environmentally friendly, durable paints that ensure a stunning finish with lasting appeal.

“We’re excited to expand our service area and bring our top-tier painting services to Battlefield,” said the owner of Pro Painting & More. “Our team is committed to delivering the highest quality work, whether it’s enhancing the interior of a home, revitalizing the exterior, or giving kitchens a fresh new look with beautifully painted cabinets.”

Pro Painting & More’s commitment to customer satisfaction and superior results has made it a trusted name in the painting industry. As they continue to grow, they are proud to offer the Battlefield community access to reliable, skilled painting services that elevate the look and feel of any space.

For more information on Pro Painting & More’s services or to schedule a consultation, visit their website or contact their customer service team today.

Media Contact
Company Name: Pro Painting & More
Contact Person: Donnie Curran
Email: Send Email
Phone: (417) 890-2051
Address:2665 W Old Limey Rd
City: Battlefield
State: MO
Country: United States
Website: https://www.propaintingusa.com/

Richard Hanson and Andrew Hanson with Generations Wealth Management, Highlight Comprehensive Family Financial Planning in TV Interview

Henderson, NV – Richard Hanson and his son Andrew Hanson represent a father-and-son financial advisory team at Generations Wealth Management Group. Together, they specialize in personalized family and generational financial planning, offering a comprehensive, collaborative approach to help families secure their financial futures.

The Hansons were recently featured in an interview on Fox’s “The Morning Blend,” where they emphasized their dedication to treating clients like family. During the interview, Richard Hanson shared, “Our mission is simple—to treat each client as one of our own. Financial planning is more than numbers; it’s about understanding a family’s unique needs and helping them create a legacy that stands the test of time.”

Living retirement to the fullest is not merely about reaching retirement age; it requires a comprehensive approach that begins long before the actual retirement date. Proactive planning is essential, focusing on key areas such as income, expenses, and preparing for potential market volatility. Here’s how these elements come together to create a fulfilling retirement experience.

The journey to a fulfilling retirement starts well before the retirement date. Engaging in planning and discussions about what retirement will look like is crucial. This includes understanding personal goals, aspirations, and the lifestyle one wishes to maintain. Individuals can establish a solid foundation for their retirement years by starting early.

A significant aspect of proactive planning is managing income and expenses. Hanson points out that controlling these financial elements is vital for a healthy retirement. This means ensuring enough income to cover living expenses while planning sustainable withdrawals from investment accounts. By keeping withdrawals manageable, retirees can mitigate the impact of market fluctuations on their financial health. Ultimately, proactive planning leads to peace of mind. When retirees know they have prepared for various scenarios—such as unexpected expenses, health issues, or market downturns—they can focus on enjoying their retirement. Hanson highlights that doing the “dirty work” ahead of time allows individuals to live confidently, knowing they have a solid plan.

Generations Wealth Management Group tailors strategies to individual families, ensuring a customized experience aimed at achieving long-term financial goals. By fostering a collaborative process, Richard and Andrew guide their clients through crucial decisions that impact future generations, making financial planning a truly family-first experience.

About:

Two generations of trusted Hanson financial professionals serve multiple generations of clients concerned with financial goals, wealth management, safety, security, and estate planning. Richard Hanson, President of Generations Financial & Insurance Services, began his career in 1983. He is currently an educational speaker on retirement and money management. Mr. Hanson is Designated as a Certified Senior Advisor (CSA). He Currently Holds a membership with the National Association of Life Underwriters. 2011 Insurmark Hall of Fame Inductee. Andrew Hanson, Vice President of Generations Financial began his career in January 2016. He is the Head of Case Design Team & Digital Outreach. He hosts numerous Seminars educating our community on such subjects as; Social Security, RMD’s, Asset Protection, Legacy Protection, College Funding and IRA / 401(k) Analysis.

Learn more: https://www.generationswealthmgt.com/

Registered Representative & Securities Offered Through Capital Synergy Partners, Member FINRA/SIPC, 2860 Michelle Dr. Suite 150 Irvine, CA 92606, Phone: 888-277-1974

Generations Wealth Management Group and Capital Synergy Partners are Unaffiliated Entities.

Media Contact
Company Name: Marketing Huddle, LLC
Contact Person: Mike Saunders, MBA
Email: Send Email
Phone: 7202323112
Country: United States
Website: https://www.AuthorityPositioningCoach.com